Some two years ago, I wrote a warning about Fenbendazole because feeding it for 4 days to my homing pigeons had killed half of them. Since then, I did analyze the problem thoroughly to deal with the insurance company of the veterinarian who prescribed the drug without knowing its mode of action. Here is why one should be very careful in using it, as it can be harmful also to humans and mammals, even though these tolerate higher dosages than birds.
Fenbendazole is a cytostatic drug with a chemical structure resembling the well-known Docetaxel. But oncologists do have good reasons not to give anticancer chemotherapy drugs orally but infuse patients in well-timed intervals. As already pointed out in earlier comment in this forum, Fenben is a tubulin blocker. Tubulin is an important protein found in many cells. It builds up the transport ways within metabolically active cells, and is essential for aligning the chromosomes during cell division. So what happens if one consumes Fenben (even by using the recommended dosages suggested by Joe Tippens)?
It won’t affect much the upper part of the digestive tract and the stomach but its first target will be the billions of cells lining the small intestine and taking up the various nutrients. These cells (technically known as enterocytes) depend on tubulin-constructed beltways to transport the nutrients to the tissue beneath from where they enter blood (to the liver) and lymph vessels. These cells also transport some amount of orally ingested Fenben (maximally 20-30%) that is delivered to the liver and other body systems but then Fenben shuts down their transfer machinery and (fortunately) limits further uptake. Thus, the first effect is that nutrient uptake is restricted and that many enterocytes die and are shed into the smaller intestine. No big deal for most of us with some overweight: loosing a pound or two is not so bad after all, and occasional diarrhea may occur (what happens to other cells in the body facing Fenben will be explained later). But first the lost enterocytes must be replaced and here begin the problems.
The cells lining the small intestine are normally replaced totally within 3-4 days. New cells are generated in small pits at the bottom of the cell lining, known a Lieberkuhn’s crypts, each one harbouring 12-16 stem cells. These divide constantly in a 24h-rhythm pushing up new cells in order to replace the shed enterocytes. The stem cells react very badly to ingesting Fenben since the drug, like any other chemotherapy drug, blocks cell division; in this case by preventing the aligning of chromosomes along the so-called spindles made by tubulin. If this happens, stem cells invoke a very old safety self-destruction program called apoptosis and die. But the crypt stem cells do not work in synchrony and some of these cells will be in a cell division stage during which they do not build up these spindles, being thus temporarily unaffected by Fenben. But about half of them (say 8) will be inactivated by a first day of Fenben. The next day of consumption, the Fenben will kill again half of the four remaining cells, and after days 3 or 4 most of these stem cells will be gone and the small intestine will be dangerously damaged, indicated by numerous side effects such as vomiting and cramps. Fenben users (for treating themselves or pets) have probably noticed the stringent warnings of the manufacturers to stop medication after 3 days and pausing for prolonged periods, of course not indicating the reasons. They know exactly what is going on and must make sure that people permit for their pets recovery time for stem cells and enterocytes. But what can be read in the instructions is always how the drug kills the worms and nothing about the risks for consumers…
One can also ask what happens when Fenben gets into the body system. As said before, there will be a first wave making it, and their preferred targets will be cells having an active metabolism (for those having had courses in histology, these are the cells with bright cell nuclei found in liver, kidney and the brain). The first array of such cells is located in the liver, and so Fenben will inactivate a bunch of them and may cause some transient problems in liver function, see also Yamaguchi et al. 2021 below. But this organ will recuperate because its stem cells work at a slower pace. The much more dangerous effects take place when Fenben, after some days of intake, enters through the destroyed cell lining of the small intestine. Then it will attack seriously the second stem cell population working always at full speed, namely the cells producing white and red blood cells, the so-called hematopoietic system in bone marrow, spleen and lymph nodes. Thus Fenben in the body system is clearly immunotoxic. The loss of immuno-competent stem cells is doubly dangerous because many bacteria and viruses are entering the body that otherwise would be confined to the intestine. Immunotoxicity is in fact the main factor that kills birds after prolonged feeding of Fenben as they continue to die for 2-3 weeks by many bagatelle infections, comparable to HIV-infected people.
But why are birds more sensitive to Fenben intoxication? The reasons are not well known. For one, the body temperature is much higher than in mammals. Secondly, the bird species apparently affected most by Fenben are those feeding the offspring from a mixture of food and shed cells in their crops, a feature facilitating toxic Fenben uptake in throat or crop. Since homing pigeons and parrots can be expensive (up to 1.7 Mio Euro for a top racing pigeon), the manufacturers have issued warnings of treating those birds with Fenben, yet without explaining why.
Finally, one might wonder why there have been not more reports about dangerous side effects in humans. The chief reason is that Fenben is not approved for use in humans, and so there are no clinical studies. There is also no reason to study in-depth damages of the stem cells and cells lining the small intestine. For those interested in the matter, even normal chemotherapy by infusion damages seriously the intestinal stem cells (Keefe et al. 2000, below). A second reason is that repeated application of Fenben during restricted time windows considered as “safe” is likely to cause drug resistance. This means that intestinal cells do no longer absorb it or they use protective mechanisms to kick it out of the cell after entry. In this case, the drug fulfills the claims of the manufacturers that it only harms worms but will no longer enter the body systems to kill cancer cells. But we PCa patients have certainly other problems than intestinal worms and should preferably rely on clinically proven treatments.
Lastly, advocates of Fenben point to the fact that the suggested safe dewormer drug kills cancer cells in culture. But it would be difficult to find any tubulin blocking substance that is not killing cancer cells in culture – so what? In conclusion, everyone is free to swallow drugs known to kill intestinal and stem cells of the immune system. But the consumer should know what the drug is really doing in the body and public information about this is woefully missing, chiefly due to withheld information by the producer. Moreover, positive effects, if any, by killing prostate cancer cells (which divide rather slowly) will be uncontrollable and marred by hidden immunotoxic effects. Interestingly, the claims of Joe Tippens could apply to any other substance taken against cancer: about 5-10% of all types of treated tumors can show long-lasting remissions regardless of the treatment (Coventry and Ashton 2012, see below). But this is another topic yet probably more interesting for many of us than the discussion around Fenben.
Coventry B, Ashdown. Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res. 2012;4:137-149. doi.org/10.2147/CMAR.S31887
Keefe DM, Brealey J, Goland GJ, Cummins AG (2000) Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47:632-637. doi.org/10.1136/gut.47.5.632
Yamaguchi T, Shimizu J, Oya Y, Horio Y, Hida T (2021) Drug-induced liver injury in a patient with non-small cell lung cancer after the self-administration of fenbendazole based on social media information. Case Reports in Oncology 14:886-891. doi.org/10.1159/000516276